Clinical Trial

Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2022 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to evaluate the effects of oral berberine (BBR) and inulin combined with insulin therapy on diabetes care in patients with LADA.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-01-05; most recent amendment 2022-02-08.
Status change: Withdrawn → Not Yet Recruiting 2021-08-10
Status change: Not Yet Recruiting → Withdrawn 2021-08-02
Trial Details
NCT Number NCT04698330
Lead Sponsor Second Xiangya Hospital of Central South University
Conditions Type 1 Diabetes Mellitus, Autoimmune Diabetes
Enrollment 240 participants
Start Date 2022-05
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-02-25